LOGIN  |  REGISTER
C4 Therapeutics

Rani Therapeutics to Participate in September Investor Conferences

September 03, 2024 | Last Trade: US$2.30 0.10 -4.17

SAN JOSE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the Company will participate in two upcoming investor conferences in September 2024. These conferences include:

H.C. Wainwright 26th Annual Global Investment Conference
Location: Lotte New York Palace Hotel, New York, NY
Date: Tuesday, September 10, 2024 at 4:30 pm E.T.
Format: Company Presentation and 1x1 Investor Meetings
Presenter: Chief Executive Officer, Talat Imran

2024 Cantor Global Healthcare Conference
Location: InterContinental Barclay Hotel, New York, NY
Date: Wednesday, September 18, 2024 at 11:30am E.T.
Format: Fireside Chat and 1x1 Investor Meetings
Presenter: Chief Executive Officer, Talat Imran

Interested parties can register for and access the live webcasts for these conferences by visiting the “Events” section of the Rani Therapeutics website. The webcast replays will be available after the conclusion of the respective presentations.

About Rani Therapeutics

Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill® capsule, which is a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill® capsule technology. For more information, visit www.ranitherapeutics.com

Investor Contact:

This email address is being protected from spambots. You need JavaScript enabled to view it. 

Media Contact:

This email address is being protected from spambots. You need JavaScript enabled to view it. 

Recursion

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB